A multicenter, open-label, 24-week study to evaluate the efficacy and safety of indinavir sulfate [indinavir] 800 mg and ritonavir 200 mg b.i.d. [twice daily] plus 2 NRTIs [nucleoside reverse transcriptase inhibitors] b.i.d. in HIV-1 infected individuals who require early treatment intervention

Trial Profile

A multicenter, open-label, 24-week study to evaluate the efficacy and safety of indinavir sulfate [indinavir] 800 mg and ritonavir 200 mg b.i.d. [twice daily] plus 2 NRTIs [nucleoside reverse transcriptase inhibitors] b.i.d. in HIV-1 infected individuals who require early treatment intervention

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2005

At a glance

  • Drugs Indinavir; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top